Cart
sales@molnova.com
Eciruciclib
CAS No. 1868086-40-1
Eciruciclib( —— )
Catalog No. M28496 CAS No. 1868086-40-1
Eciruciclib is an inhibitor of CDK with antitumor properties.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 198 | In Stock |
|
| 10MG | 299 | In Stock |
|
| 25MG | 509 | In Stock |
|
| 50MG | 686 | In Stock |
|
| 100MG | 910 | In Stock |
|
| 200MG | 1200 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEciruciclib
-
NoteResearch use only, not for human use.
-
Brief DescriptionEciruciclib is an inhibitor of CDK with antitumor properties.
-
DescriptionEciruciclib is an inhibitor of CDK with antitumor properties.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1868086-40-1
-
Formula Weight488.6
-
Molecular FormulaC27H33FN8
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 2 mg/mL (4.09 mM)
-
SMILESCC(C1=C2C=C(C3=NC(NC4=NC=C(CN5CCN(CC)CC5)C=C4)=NC=C3F)C=CC2=NN1C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
CDK9-IN-1
CDK9-IN-1 is a potent, selective CDK9 inhibitor with IC50 of 39 nM (CDK9/CycT1), >10-fold selectivity over CDK4 and >100-fold over CDK1/2/3/5/6/7, inhibits HIV-1 replication in cellular assays.
-
XY028-140
XY028-140 is a selective CDK4/CDK6 degrade and inhibits both CDK4/6 expression and activity in cancer cells. XY028-140 is a PROTAC connected by ligands for Cereblon and CDK.
-
NU-2058
An ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 5 uM and 12 uM respectively; inhibits human tumor cells with a mean GI50 of 13±7 uM.
